# US 2009/0263387 A1 · Neutralization of GM-CSF for the Treatment of Heart Failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0263387 A1
- Document ID: US20090263387A1
- Status: Published application
- Kind: A1
- Application number: 12/419,991
- Filed: 2009-04-07
- Published: 2009-10-22
- Earliest claimed: 2008-04-07
- Assignees: KaloBios Pharmaceuticals, Inc.
- Inventors: Christopher R. Bebbington; Geoffrey T. Yarranton
- Web page: https://patentgrep.com/patent/US20090263387A1

## CPC

- C07K 16/243: {Colony Stimulating Factors}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.

## Claims

### Claim 1

A method for treating a patient that has heart failure, is at risk for heart failure subsequent to an ischemic episode, or has a cardiomyopathy, the method comprising administering a therapeutically effective amount of a GM-CSF antagonist to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has had an ischemic episode.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient has had an acute myocardial infarction.

### Claim 4 (depends on 3)

The method of claim 3, wherein the GM-CSF antagonist is administered within twenty four hours of having the acute myocardial infarction.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient has Class II, Class III, or Class IV heart failure as determined with reference to the New York Heart Association classification.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is being treated with an angiotensin-converting enzyme (ACE) inhibitor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is an anti-GM-CSF antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibody is a monoclonal antibody.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antibody is a nanobody or a camellid antibody.

### Claim 10 (depends on 7)

The method of claim 7, wherein the antibody is an antibody fragment that is a Fab, a Fab′, a F(ab′)2, a scFv, or a dAB.

### Claim 11 (depends on 10)

The method of claim 10, wherein the antibody fragment is conjugated to polyethylene glycol.

### Claim 12 (depends on 7)

The method of claim 7, wherein the antibody has an affinity of about 100 pM to about 10 nM.

### Claim 13 (depends on 7)

The method of claim 7, wherein the antibody has an affinity of about 0.5 pM to about 100 pM.

### Claim 14 (depends on 7)

The method of claim 7, wherein the antibody is a neutralizing antibody.

### Claim 15 (depends on 7)

The method of claim 7, wherein the antibody is a recombinant or chimeric antibody.

### Claim 16 (depends on 7)

The method of claim 7, wherein the antibody comprises a human variable region.

### Claim 17 (depends on 7)

The method of claim 7, wherein the antibody comprises a human light chain constant region.

### Claim 18 (depends on 16)

The method of claim 16, wherein the antibody comprises a human heavy chain constant region.

### Claim 19 (depends on 18)

The method of claim 18, wherein the human heavy chain constant region is a gamma chain.

### Claim 20 (depends on 7)

The method of claim 7, wherein the antibody binds to the same epitope as chimeric 19/2.

### Claim 21 (depends on 20)

The method of claim 20, wherein the antibody comprises the VH and VL regions of chimeric 19/2.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antibody comprises a human heavy chain constant region.

### Claim 23 (depends on 22)

The method of claim 22, wherein the human heavy chain constant region is a gamma region.

### Claim 24 (depends on 20)

The method of claim 20, wherein the antibody comprises the VH region and VL region CDR1, CDR2, and CDR3 of chimeric 19/2.

### Claim 25 (depends on 20)

The method of claim 20, wherein the antibody comprises the VH region CDR3 and VL region CDR3 of chimeric 19/2.

### Claim 26 (depends on 7)

The method of claim 7, wherein the antibody is a human antibody.

### Claim 27 (depends on 7)

The method of claim 7, wherein the antibody has a half-life of about 7 to about 25 days.

### Claim 28 (depends on 7)

The method of claim 7, wherein the antibody is administered at a dose between about 1 mg/kg of body weight and about 10 mg/kg of body weight.

### Claim 29 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is administered intravenously.

### Claim 30 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is administered subcutaneously.

### Claim 31 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is administered intramuscularly.

### Claim 32 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is administered multiple times.

### Claim 33 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is an anti-GM-CSF receptor antibody.

### Claim 34 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is a soluble GM-CSF receptor.

### Claim 35 (depends on 1)

The method of claim 1, wherein the GM-CSF antagonist is selected from the group consisting of a cytochrome b562 antibody mimetic, an adnectin, a lipocalin scaffold antibody mimetic, a calixarene antibody mimetic, and an antibody like binding peptidomimetic.
